EZH2 is a sensitive marker of malignancy in salivary gland tumors
© Hajósi-Kalcakosz et al. 2015
Received: 10 June 2015
Accepted: 28 August 2015
Published: 17 September 2015
The immunohistochemical detection of Enhancer of zeste homologue 2 (EZH2) proved to be a useful tool to recognize the malignant nature of tumors in a wide variety of neoplasms. The histological diagnostics of salivary gland tumors is a challenging task, and a reliable marker of malignancy would be extremely helpful.
EZH2 expression was investigated in 54 malignant and 40 benign salivary gland tumors of various histological types by standard immunohistochemistry.
The majority (n = 52) of the malignant tumors stained positively, while all the investigated benign tumors were negative for EZH2.
EZH2 expression in salivary gland tumors, similarly to the tumors of other organs is not characteristic for any tumor type, but is a solid marker of the malignant nature of the tumors.
Although tumors of the salivary glands are not among the most common neoplasms, they provide a serious challenge for pathologists. The multitude of tumor types and overlapping histological features often give rise to multiple interpretations. Moreover, on occasion it can be problematic to distinguish between the benign and malignant nature of certain specimens. Of course, ancillary techniques are widely used. Certain molecular lesions have been recognized in different tumors and immunohistochemistry is applied on an everyday routine basis [1–3]. However, these techniques provide only limited help and the diagnosis is mostly determined by the H&E stained sections.
Enhancer of zeste homologue 2 (EZH2) is a widely studied histone methyl transferase [4, 5]. Recently we have reported that the immunohistochemical examination of this protein can effectively distinguish between benign and malignant hepatic tumors . Similar observations have been made in intraductal papillary neoplasms of bile ducts , effusion cytology , etc. To our knowledge, there is quite limited information on the expression of this potential tumor marker in salivary gland tumors. The available data, however, suggest that there may be a connection between the behavior of salivary gland tumors and EZH2 expression as well [9, 10]. The purpose of our study is to examine EZH2 expression in a variety of benign and malignant salivary gland tumors, and to investigate if it provides any useful information for their recognition. All 40 benign salivary gland tumors investigated were negative for EZH2, while 52 of the 54 malignant tumors proved to be positive. Based on this observation EZH2 immunohistochemistry might provide valuable information for the histological examination of salivary gland tumors.
We selected 54 (Additional file 1: Table S1) malignant and 40 benign (Additional file 2: Table S2) salivary gland tumors from the archives of the First Department of Pathology and Experimental Cancer Research, Semmelweis University (Budapest, Hungary) and Pathology Department of National Institute of Oncology (Budapest, Hungary). The study was approved by the ethics committee of the Semmelweis University. The tumors were diagnosed according to standard diagnostic criteria and immunohistochemical staining. Formalin-fixed paraffin-embedded tissue was used for the immunohistochemical reactions. Staining was performed using an automated Leica Bond immunostainer, with the Leica Bond Polymer refine detection system and 3,3′ Diaminobenzidine (DAB) as the chromogen. Antigen retrieval was achieved with Bond Epitope Retrieval Solution 2 (high pH) for 20 min. The primary antibody was a mouse monoclonal anti-EZH2 (clone 11/EZH2) from BD Biosciences (San Jose CA, USA) (dilution 1:100). The reaction resulted in nuclear staining. Scores were assigned based on the density of positivity by using negative (score =0, < 5 % of nuclei staining); weak (score = 1, 5–10 % of nuclei staining); moderate (score = 2, 11–50 % of nuclei staining); and strong (score = 3; >50 % of nuclei staining).
EZH2 immunohistochemical staining resulted in a clear nuclear reaction. The non-tumorous portion of the salivary gland tissue always remained negative. The lymphoid cells were frequently positive, as well as the nuclei of the squamous epithelium on occasional mucosal pieces on the tissue.
The epithelial components of the Warthin tumors (Fig. 1c and d) were also consistently negative, while the lymphoid follicles, especially the germinative centers, were stained for EZH2 similar to the normal lymphoid tissue. Thus, these tumors were regarded as negative, not unlike other less common benign tumors such as basal cell adenomas, oncocytomas and cystadenomas.
All the studied adenoid cystic carcinomas (n = 13) stained positively with EZH2 antibody (Fig. 2c and d). The growth pattern of the tumor had no influence on the staining. Preferential staining of the abluminal cells could be observed in a few tumors, but this feature was not consistent. Perineural invading components of the tumors were also positive.
Four of the acinic cell carcinomas (n = 5) had microcystic growth pattern, with one showing occasional papillary structures. All were variably positive. The single solid acinic cell carcinoma had, however, very few positively stained nuclei which was below our 5 % threshold. The three polymorphous low grade adenocarcinomas stained positively (Fig. 3c and d).
In case of two myoepithelial and one basal cell tumors, the malignant diagnosis was based on the high mitotic rate or invasive growth pattern. The preexistent diagnoses were nicely supported by the positive EZH2 staining. Three non-classifiable adenocarcinomas, one squamous cells carcinoma and one clear cell carcinoma also stained positively.
We have investigated the expression of EZH2 by immunohistochemistry on the most common types of salivary gland tumors. All the benign tumors (n = 40) were negative, but the majority of the malignant tumors (52/54) regardless of the histological type proved to be positive. EZH2 is the catalytic subunit of polycomb repressive complex 2 (PRC2). It catalyzes the trimethylation of lysine 27 on histone H3 (H3K27me3), and mediates transcriptional silencing [4, 5]. Gain of function mutations of EZH2 represent a promising therapeutic target in germinal center lymphomas , and increased expression of this protein has been reported in several other tumors [12–19]. It is usually an unfavorable prognostic marker. We have described that EZH2 is expressed in most of the malignant liver tumors, but it is absent from the benign tumors and reactive proliferative lesions . This reaction was useful to recognize the malignant behavior of intraductal papillary neoplasms of bile ducts , hepatic and pancreatic cystic neoplasms  and squamous cell tumors of the skin . EZH2 proved to be a unique marker of malignancy in effusion cytology . Such a reliable marker of malignant tumors would be extremely helpful for salivary gland tumors as well due to their diverse histological structure, and the common morphological overlap between benign and malignant tumors. Assessment of proliferative activity  and several other markers (Human α-defensin, maspin, RB1-inducible coiled-coil 1, etc.) [2, 23–25] has been proposed to address this problem. High expression of EZH2 detected by immunohistochemistry has been reported to predict poor survival for patients with adenoid cystic carcinoma . Increased EZH2 staining was more common in malignant myoepithelial tumors . High expression of H3K9me3 is a strong predictor of poor survival in patients with salivary adenoid cystic carcinoma . Although this DNA modification is related with another enzyme, it may indicate that the activity of histone methylation might be connected with the biological behavior of salivary gland tumors. As far as we know, our study is the first to involve a comprehensive set of salivary gland tumors. Our finding is comparable to the result found on other types of tumors. EZH2 is a highly sensitive (96.3 %) and specific (100 %) indicator of malignancy in salivary gland tumors. According to our results its positive predictive value is 100 %, while its negative predictive value is 95.24 %. The increased expression of this enzyme cannot be associated with any specific cell type, and so, similarly to the tumors of other organs, it does not provide any help for the histological classification of the tumors. Our sample size for the individual tumor types is too low to search for connection between the level of overexpression and prognosis. It is also crucial to investigate large series of tumors (e.g. basal cell adenoma v.s. carcinoma, myoepithelial, oncocytic tumors) where there is a broad gray border zone between benign and malignant tumors making the distinction between them highly challenging. Our result indicates that it would be worth performing such studies along with elucidating the molecular mechanism of EZH2 upregulation in salivary gland tumors. Such studies are most advanced in case of follicular lymphomas, where EZH2 has become a potential target of therapeutic approaches .
Interestingly, increased EZH2 expression has been reported in oral squamous cell carcinomas compared to dysplastic and normal epithelium . The judgment of the squamous epithelium is another shaky field of oral pathology. In our slides the accidental non tumorous epithelium was always strongly decorated by the EZH2 antibody.
In conclusion, the majority of malignant salivary gland tumors is EZH2 positive. This immunohistochemical reaction may be a useful tool to recognize them; however, it does not help to distinguish between different varieties of salivary gland carcinomas.
The authors thank Elizabeth A. Conner and Susan H. Garfield for correcting the English language.
Supported by Hungarian Scientific Research Fund (OTKA K100931 and PD109201). This research was realized in the frames of TÁMOP 4.2.4. A/1-11-1-2012-0001 „National Excellence Program”.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Cheuk W, Chan JKC. Advances in salivary gland pathology. Histopathology. 2007;51:1–20.View ArticlePubMedGoogle Scholar
- Nagao T, Sato E, Inoue R, Oshiro H, Takahashi RH, Nagai T, et al. Immunohistochemical analysis of salivary gland tumors: Application for surgical pathology practice. Acta Histochem Cytochem. 2012;45:269–82.PubMed CentralView ArticlePubMedGoogle Scholar
- Simpson RHW, Skálová A, Di Palma S, Leivo I. Recent advances in the diagnostic pathology of salivary carcinomas. Virchows Arch. 2014;465:371–84.View ArticlePubMedGoogle Scholar
- Sparmann A, van Lohiuzen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6:846–56.View ArticlePubMedGoogle Scholar
- Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008;647:21–9.View ArticlePubMedGoogle Scholar
- Hajósi-Kalcakosz S, Dezső K, Bugyik E, Bödör C, Paku S, Pávai Z, et al. Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors. Diagn Pathol. 2012;7:86.PubMed CentralView ArticlePubMedGoogle Scholar
- Sasaki M, Matsubara T, Yoneda N, Nomoto K, Tsuneyama K, Sato Y, et al. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behavior in intraductal papillary neoplasm of the bile duct. Histopathology. 2013;62:446–57.View ArticlePubMedGoogle Scholar
- Jiang H, Gupta R, Somma J. EZH2, a unique marker of malignancy in effusion cytology. Diagn Cytopathol. 2014;42:111–6.View ArticlePubMedGoogle Scholar
- Vékony H, Raaphorst FM, Otte AP, van Lohuizen M, Leemans CR, van der Waal I, et al. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. J Clin Pathol. 2008;61:744–9.View ArticlePubMedGoogle Scholar
- Vékony H, Röser K, Löniing T, Raaphorst FM, Leemans CR, Van der Waal I, et al. Deregulated expression of p16INK4a and p53 pathway members in benign and malignant myoepithelial tumours of the salivary glands. Histopathol. 2008;53:658–66.View ArticleGoogle Scholar
- Bödör C, Grossmann V, Popov N, Okosun J, O’Riain C, Tan K, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122:3165–8.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang H, Albadine R, Magheli A, Guzzo TJ, Ball MW, Hinz S, et al. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of bladder. Urol Oncol. 2012;30:428–33.View ArticlePubMedGoogle Scholar
- Yamada A, Fujii S, Daiko H, Nishimura M, Chiba T, Ochiai A. Aberrant expressions of EZH2 is associated with a poor outcome and p53 alterations in squamous cell carcinoma of the esophagus. Int J Oncol. 2011;38:345–53.PubMedGoogle Scholar
- Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H. Expression of the enhancer zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 2006;97:484–91.View ArticlePubMedGoogle Scholar
- Orzan F, Pellegatta S, Poliani PL, Pisati F, Caldera V, Menghi F, et al. Enhancer of zeste homolog 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol. 2011;37:381–94.View ArticlePubMedGoogle Scholar
- Wagener N, Macher-Goeppinger S, Pritsch M, Hüsing J, Hoppe-Seyler K, Schirmacher P, et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer. 2010;10:524.PubMed CentralView ArticlePubMedGoogle Scholar
- Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, et al. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathological significance. Cancer. 2010;116:3015–24.View ArticlePubMedGoogle Scholar
- Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol. 2010;16:2421–7.PubMed CentralView ArticlePubMedGoogle Scholar
- Gonzalez ME, DuPrie ML, Krueger H, Merajver SD, Ventura AC, Toy KA, et al. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res. 2011;71:2360–70.PubMed CentralView ArticlePubMedGoogle Scholar
- Matsubara T, Sato Y, Sasaki M, Harada K, Nomoto K, Tsuneyama K, et al. Immunohistochemical characteristics and malignant progression of hepatic cystic neoplasms in comparison with pancreatic counterparts. Hum Pathol. 2012;43:2177–86.View ArticlePubMedGoogle Scholar
- Athanassiadou AM, Lazaris AC, Patsouris E, Tsipis A, Chelidonis G, Aroni K. Significance of cyclooxygenase 2, EZH-2 polycomb group and p53 expression in actinic keratosis and squamous cell carcinomas of the skin. Am J Dermatopathol. 2013;35:425–31.View ArticlePubMedGoogle Scholar
- Sakálová A, Leivo I. Cell proliferation in salivary gland tumors. Gen Diagn Pathol. 1996;142:7–16.Google Scholar
- Winter J, Pantelis A, Kraus D, Reckenbeil J, Reich R, Jepsen S, et al. Human α-defensin (DEFA) gene expression helps to characterize benign and malignant salivary gland tumours. BMC Cancer. 2012;12:465.PubMed CentralView ArticlePubMedGoogle Scholar
- Schwarz S, Ettl T, Kleisasser N, Reichert TE, Driemel O. Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol. 2008;44:563–70.View ArticlePubMedGoogle Scholar
- Takata T, Kudo Y, Zhao M, Ogawa I, Miyauchi M, Sato S, et al. Reduced expression of p27(Kip1) protein in relation to salivary adenoid cystic carcinoma metastasis. Cancer. 1999;86:928–35.View ArticlePubMedGoogle Scholar
- Xia R, Zhou R, Tian Z, Zhang C, Wang L, Hu Y, et al. High expression of H3K9me3 is a strong predictor of poor survival in patients with salivary adenoid cystic carcinoma. Arch Pathol Lab Med. 2013;137:1761–9.View ArticlePubMedGoogle Scholar
- Shiogama S, Yoshiba S, Soga D, Motohashi H, Shintani S. Aberrant expression of EZH2 is associated with pathological findings and p53 alteration. Anticancer Res. 2013;33:4309–17.PubMedGoogle Scholar